天啊，搞了半天莫德納疫苗在今天以前一直都沒有被FDA正式批准啊！接種了該疫苗的人此前知道不？
- 主题发起人 TianK
- 开始时间
- 注册
- 2005-11-23
- 消息
- 30,291
- 荣誉分数
- 7,455
- 声望点数
- 373
很有可能，去年6月，德国的一个疫苗赶上Delta，在老龄组效果不佳，总体没有达到50%，放弃了。
ABANDONED
VACCINE NAME: CVnCoV
EFFICACY: 48%
DOSE: 2 doses, 4 weeks apart
TYPE: Muscle injection
STORAGE: Stable at least 3 months at 36–46°F (2–8°C)
The German company CureVac generated a lot of hope for its mRNA vaccine for Covid-19 in 2020, only to see it deliver disappointing results in clinical trials the following year.
The company, founded in 2001, had years of experience developing experimental mRNA vaccines for a host of diseases. In early 2020, they began work on a Covid-19 vaccine, called CVnCoV. In March, the Trump administration unsuccessfully tried to entice CureVac to move its research on their mRNA vaccine from Germany to the United States.
The company plowed ahead with its work in Germany, seeing responses to the vaccine in mice and monkeys before launching clinical trials in July. CVnCoV showed promise in several respects: it could remain stable in a refrigerator rather than a freezer, and preliminary studies suggested it would work well at a low dose, reducing its cost.
In December, CureVac launched a Phase 3 trial, recruiting up to 36,500 volunteers in Germany. The European Union began a rolling review in February, intended to speed up approval if the Phase 3 trial delivers positive results.
Meanwhile, CureVac prepared for mass production of the vaccine. The company negotiated a deal to provide the European Union with up to 400 million doses of their vaccine. They projected manufacturing up to 300 million doses in 2021 and up to a billion doses the following year. Starting in January 2021, CureVac forged a series of partnerships with pharmaceutical giants Bayer, Celonic, GSK, and Novartis, to support the production of their vaccine and develop new ones against coronavirus variants.
In June 2021, CureVac reported disappointing results from their Phase 3 trial. Overall, CVnCoV had an efficacy of just 48 percent against Covid-19. It proved somewhat better for younger volunteers: For those between the ages of 18 and 60, the efficacy rose to 53 percent. In that group, the researchers also found the vaccine provided 100 percent protection against hospitalization and death. Researchers later pointed to the vaccine dosage along with the rise of new variants as potential reasons for the low efficacy. On Sept. 14, CureVac announced that it had cancelled its manufacturing deals with Celonic and German company Wacker, citing a decline in demand for CVnCoV.
Despite the disappointing results, the company moved ahead with preparing an application to the European Union for emergency authorization for the use of the vaccine in people 60 and under. But European regulators gave no indication they would continue speeding along their review. As a result, on Oct. 12, CureVac announced that it would withdraw CVnCoV from the regulatory approval process.
Instead, CureVac is focusing its efforts on a next-generation vaccine for Covid-19, called CV2CoV, that it is developing with GSK. This updated version produces more spike proteins, and thus a stronger immune response. In November, researchers at Harvard published a study in the journal Nature showing that monkeys given CV2CoV produced antibodies to the coronavirus at a level comparable to the Comirnaty vaccine from Pfizer and BioNTech. Reuters reported in November that CureVac was planning on starting a Phase 1 trial on CV2nCoV within the next few months.
Updated Nov. 26
可是死是防不了的啊。任何病都可导致死，就是死的机率高不高而已。摔了头的死亡率高于扭了脚的。
应该是此苗虽不能完全阻止死亡，但能降低死亡率吧。但考虑到此毒的致死率很低，官方数据不明，民间有传最大约1％吧(你们如有更准确数据，请通知一下)，死的命都是宝贵的命，死一个不比死一千个更让人庆幸。无论死多少人，都要为之伤心难过。可是动用100%的接种率，来对付1％的死亡率，理论上讲精诚可贵，在现实上不太可行吧，有点儿理想主义色彩。既然任何病都可致死，也许把这么大的阵仗用到对付高致死率的疾控上更有效点。
应该是此苗虽不能完全阻止死亡，但能降低死亡率吧。但考虑到此毒的致死率很低，官方数据不明，民间有传最大约1％吧(你们如有更准确数据，请通知一下)，死的命都是宝贵的命，死一个不比死一千个更让人庆幸。无论死多少人，都要为之伤心难过。可是动用100%的接种率，来对付1％的死亡率，理论上讲精诚可贵，在现实上不太可行吧，有点儿理想主义色彩。既然任何病都可致死，也许把这么大的阵仗用到对付高致死率的疾控上更有效点。
嗯。不知象印度、日本等国家可否参照？哪个国家没有大规模施打针对DELTA毒的疫苗，要有这样的数据就可对比？
我指，哪个国家没有大规模施打针对DELTA毒的疫苗，日本和印度属于这样的国家吗？